Recro Pharma Gross profit (Q3, 2018)9.8 M

Recro Pharma Gross profit margin (Q3, 2018), %53.7%

Recro Pharma Net income (Q3, 2018)-13.3 M

Recro Pharma EBIT (Q3, 2018)-13.6 M

Recro Pharma Cash, 30-Sep-201835.8 M

Recro Pharma EV183.8 M

Recro Pharma revenue breakdown by business segment: 97.5% from Manufacturing, royalty and profit sharing revenue and 2.5% from Other

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|

## Revenue | 52.0m | 69.3m | 71.8m | |

| 33% | |||

## Cost of goods sold | 28.1m | 37.2m | 38.2m | |

## Gross profit | 23.9m | 32.2m | 33.6m | |

| 46% | 46% | 47% | |

## R&D expense | 7.9m | 12.3m | 33.3m | 33.1m |

## General and administrative expense | 4.0m | 13.0m | 12.7m | 25.4m |

## Operating expense total | 11.9m | 58.9m | 95.1m | 112.1m |

## Depreciation and amortization | 1.9m | 2.6m | 2.6m | |

## EBIT | (11.9m) | (7.0m) | (25.8m) | (40.3m) |

| (13%) | (37%) | (56%) | |

## Interest expense | 4.3m | 5.6m | 5.6m | 12.0m |

## Interest income | 10.5k | 12.0k | 49.0k | 385.0k |

## Pre tax profit | (16.1m) | (12.5m) | (31.3m) | (52.0m) |

## Income tax expense | 15.6m | 1.1m | 1.9m | |

## Net Income | (16.1m) | 3.0m | (30.2m) | (50.1m) |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|

## Cash | 19.7m | 19.8m | 64.5m | 61.0m |

## Accounts Receivable | 89.6k | 8.6m | 10.4m | 9.7m |

## Inventories | 9.0m | 1.1m | 9.8m | |

## Current Assets | 20.4m | 38.7m | 84.8m | 87.3m |

## PP&E | 37.9m | 37.3m | 39.1m | |

## Goodwill | 6.4m | 6.4m | 6.4m | |

## Total Assets | 20.4m | 138.7m | 183.0m | 186.2m |

## Accounts Payable | 869.9k | 1.6m | 4.1m | 8.0m |

## Short-term debt | 4.5m | 2.2m | ||

## Current Liabilities | 1.4m | 9.5m | 16.3m | 49.9m |

## Long-term debt | 11.9m | 25.2m | 22.2m | 53.6m |

## Total Debt | 11.9m | 29.8m | 24.4m | 53.6m |

## Total Liabilities | 111.4m | 157.4m | ||

## Common Stock | 77.1k | 92.0k | 190.0k | |

## Additional Paid-in Capital | 52.9m | 71.3m | 132.7m | 140.0m |

## Retained Earnings | (34.1m) | (31.1m) | (61.3m) | (111.3m) |

## Total Equity | 18.9m | 40.4m | 71.6m | 28.8m |

## Debt to Equity Ratio | 0.6 x | 0.7 x | 0.3 x | 1.9 x |

## Debt to Assets Ratio | 0.6 x | 0.2 x | 0.1 x | 0.3 x |

## Financial Leverage | 1.1 x | 3.4 x | 2.6 x | 6.5 x |

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 |
---|---|---|---|---|

## Net Income | (16.1m) | 3.0m | (30.2m) | (50.1m) |

## Depreciation and Amortization | 1.4k | 4.1m | 5.0m | 4.9m |

## Accounts Receivable | (51.2k) | 4.0m | (1.8m) | 725.0k |

## Inventories | 1.3m | (325.0k) | (1.1m) | |

## Accounts Payable | 1.1m | 2.2m | 8.5m | |

## Cash From Operating Activities | (10.9m) | 8.5m | (3.2m) | |

## Purchases of PP&E | (2.4m) | (3.8m) | (6.2m) | |

## Cash From Investing Activities | (55.1m) | (3.8m) | (10.3m) | |

## Long-term Borrowings | (16.3m) | (6.3m) | (27.3m) | |

## Cash From Financing Activities | 30.5m | 46.7m | 51.7m | 23.9m |

## Interest Paid | 4.9m | 4.5m | 5.3m | |

## Income Taxes Paid | 467.0k |

USD | Y, 2018 |
---|---|

## EV/EBIT | -13.6 x |

## EV/CFO | -5.2 x |

## Debt/Equity | 4 x |

## Debt/Assets | 0.3 x |

## Financial Leverage | 13 x |

Report incorrect company information

FY, 2016 | |
---|---|

## Patents Issued | 13 |

- Source: SEC Filings

Report incorrect company information